Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Adaptive Design Study for the Assessment of the Safety, Tolerability and Pharmacokinetics of RYI-018 after Single Dosing in Healthy Volunteers and Repeat Dosing in Subjects with Non-Alcoholic Fatty Liver Disease (NAFLD)

Next Previous
Trial Profile

An Adaptive Design Study for the Assessment of the Safety, Tolerability and Pharmacokinetics of RYI-018 after Single Dosing in Healthy Volunteers and Repeat Dosing in Subjects with Non-Alcoholic Fatty Liver Disease (NAFLD)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 06 Oct 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nimacimab (Primary)
  • Indications Non-alcoholic fatty liver disease
  • Focus Adverse reactions; First in man
  • Sponsors Bird Rock Bio

Most Recent Events

  • 13 Sep 2018 According to a Bird Rock Bio media release, the company announced today the it has successfully completed its final patient visit in this study.
  • 13 Sep 2018 According to a Bird Rock Bio media release, study results from the clinical trial are anticipated prior to the American Society of Nephrology's "Kidney Week" in October and AASLD's The Liver Meeting 2018 in November 2018.
  • 13 Sep 2018 Status changed from active, no longer recruiting to completed, according to a Bird Rock Bio media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top